Compare Inovio Pharmaceuticals Inc (INO) vs Standard Lithium Ltd (SLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Standard Lithium Ltd — how do they compare? Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M), while Standard Lithium Ltd trades at $1.58 (market cap $398.07M). The key difference: Standard Lithium Ltd is far larger — about 3.5× Inovio Pharmaceuticals Inc's market cap, and Inovio Pharmaceuticals Inc is trading nearer its 52-week high, Standard Lithium Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Standard Lithium Ltd for 23 Days on average.
| INO | SLI | |
|---|---|---|
Market Cap | $112.19M | $398.07M |
Volume | 3,201,278 | 1,564,155 |
Sector | Health | Basic Materials |
52-Week High | $2.65 | $5.65 |
52-Week Low | $0.66 | $1.61 |
Typical Hold Time | 43 Days | 23 Days |
Enterprise Value | $83.51M | $260.98M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO Pharmaceuticals trades at $1.09, down 5.63% today, with a bearish technical outlook despite positive analyst sentiment. The company faces significant fundamental challenges with minimal revenue of $65,340 in 2025 and substantial losses of $84.95 million. Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis, which could transform the company's prospects if approved.
Investment outlook hinges on FDA approval of INO-3107, with analysts maintaining a $2.75 consensus target representing 152% upside. However, persistent cash burn and negative profitability metrics pose substantial risks. The stock offers high-risk, high-reward potential for investors comfortable with binary regulatory outcomes in biotech.
Standard Lithium (SLI) trades at $1.58, down 4.24% today, with a bearish technical signal but bullish oscillators. The company shows negative profitability metrics with ROE at -15.55% and net income of -$48.40M for 2025, though recent quarterly EPS have beaten expectations. Positive developments include progress toward a final investment decision for the South West Arkansas lithium project by end of 2026 and expanded offtake agreements.
The outlook is mixed: analyst consensus is strongly bullish with a $3.83 price target (142% upside), but execution risks remain high as the company transitions to production. Key risks include project delays, funding needs, and negative cash flow from operations. The stock offers high potential reward but requires careful risk assessment given pre-revenue status.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →
